Targeted Delivery of c(RGDfk)‐Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy (Adv. Sci. 12/2025)

Targeted Drug Delivery to the Bone Marrow In article number 2409895, Liu Huiwen, Zhiqing Pang, Yu Hu, and co-workers introduce an innovative bone marrow-targeting strategy that utilizes c(RGDfk)-modified liposomes as therapeutic carriers. These liposomes (the cargo) exploit aging neutrophils (the purple cells), known for their intrinsic ability to home to the bone marrow, as natural transport vehicles. This approach outperformed conventional drug delivery systems by enhancing precision and minimizing off-target effects.